Is choline kinase alpha a drug target for obesity?

Choline kinase alpha (ChoKα) is a therapeutic target being developed for a variety of diseases, from cancer to rheumatoid arthritis and from parasites to bacterial infections. Nevertheless, the therapeutic potential of this drug target seems not exhausted and may end up as a possible solution for a...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in endocrinology (Lausanne) 2024-11, Vol.15, p.1492753
Main Authors: Lacal, Juan Carlos, Ibrahim, Salam A, Zimmerman, Tahl
Format: Article
Language:English
Subjects:
adipogenesis
Animals
choline
choline kinase
Choline Kinase - antagonists & inhibitors
Choline Kinase - metabolism
Endocrinology
Humans
obesity
Obesity - drug therapy
thermogenesis
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c350t-fc9fc31b625539813f28097272d689c0070f32f3da2be1ad6536bd9122cba4e03
container_end_page
container_issue
container_start_page 1492753
container_title Frontiers in endocrinology (Lausanne)
container_volume 15
creator Lacal, Juan Carlos
Ibrahim, Salam A
Zimmerman, Tahl
description Choline kinase alpha (ChoKα) is a therapeutic target being developed for a variety of diseases, from cancer to rheumatoid arthritis and from parasites to bacterial infections. Nevertheless, the therapeutic potential of this drug target seems not exhausted and may end up as a possible solution for a larger variety of conditions. Here we present our working model for how ChoKα could play a role in obesity and for how drugs being developed as therapeutics for other diseases using ChoKα as a target, could be repurposed as prophylactic treatments for obesity. We also present preliminary observations in support of our model.
doi_str_mv 10.3389/fendo.2024.1492753
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_e3142b039af0463bb73200f57a484c67</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_e3142b039af0463bb73200f57a484c67</doaj_id><sourcerecordid>3131501748</sourcerecordid><originalsourceid>FETCH-LOGICAL-c350t-fc9fc31b625539813f28097272d689c0070f32f3da2be1ad6536bd9122cba4e03</originalsourceid><addsrcrecordid>eNpVkU1vEzEQhi0EolXpH-CA9sglYTzjz1OFKj4iVeICZ8v22smWzTrYG6T-e5ImVK0vtsbvPDPSw9h7DksiYz_lNPVliYBiyYVFLekVu-RKiQWSxdfP3hfsurV7OBwB3Frzll2QlcoYhEuGq9bFTRmHKXW_h8m31Plxt_Gd7_q6X3ezr-s0d7nUroTUhvnh5h17k_3Y0vX5vmK_vn75eft9cffj2-r2890ikoR5kaPNkXhQKCVZwymjAatRY6-MjQAaMmGm3mNI3PdKkgq95YgxeJGArtjqxO2Lv3e7Omx9fXDFD-6xUOra-ToPcUwuERcYgKzPIBSFoAkBstReGBGVPrBuTqzdPmxTH9M0Vz--gL78mYaNW5e_jnOpFZfmQPh4JtTyZ5_a7LZDi2kc_ZTKvjnixCVwLY5RPEVjLa3VlJ_mcHBHee5RnjvKc2d5h6YPzzd8avmviv4BaM-UMw</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3131501748</pqid></control><display><type>article</type><title>Is choline kinase alpha a drug target for obesity?</title><source>PubMed Central Free</source><creator>Lacal, Juan Carlos ; Ibrahim, Salam A ; Zimmerman, Tahl</creator><creatorcontrib>Lacal, Juan Carlos ; Ibrahim, Salam A ; Zimmerman, Tahl</creatorcontrib><description>Choline kinase alpha (ChoKα) is a therapeutic target being developed for a variety of diseases, from cancer to rheumatoid arthritis and from parasites to bacterial infections. Nevertheless, the therapeutic potential of this drug target seems not exhausted and may end up as a possible solution for a larger variety of conditions. Here we present our working model for how ChoKα could play a role in obesity and for how drugs being developed as therapeutics for other diseases using ChoKα as a target, could be repurposed as prophylactic treatments for obesity. We also present preliminary observations in support of our model.</description><identifier>ISSN: 1664-2392</identifier><identifier>EISSN: 1664-2392</identifier><identifier>DOI: 10.3389/fendo.2024.1492753</identifier><identifier>PMID: 39568820</identifier><language>eng</language><publisher>Switzerland: Frontiers Media S.A</publisher><subject>adipogenesis ; Animals ; choline ; choline kinase ; Choline Kinase - antagonists &amp; inhibitors ; Choline Kinase - metabolism ; Endocrinology ; Humans ; obesity ; Obesity - drug therapy ; thermogenesis</subject><ispartof>Frontiers in endocrinology (Lausanne), 2024-11, Vol.15, p.1492753</ispartof><rights>Copyright © 2024 Lacal, Ibrahim and Zimmerman.</rights><rights>Copyright © 2024 Lacal, Ibrahim and Zimmerman 2024 Lacal, Ibrahim and Zimmerman</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c350t-fc9fc31b625539813f28097272d689c0070f32f3da2be1ad6536bd9122cba4e03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11576158/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11576158/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39568820$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lacal, Juan Carlos</creatorcontrib><creatorcontrib>Ibrahim, Salam A</creatorcontrib><creatorcontrib>Zimmerman, Tahl</creatorcontrib><title>Is choline kinase alpha a drug target for obesity?</title><title>Frontiers in endocrinology (Lausanne)</title><addtitle>Front Endocrinol (Lausanne)</addtitle><description>Choline kinase alpha (ChoKα) is a therapeutic target being developed for a variety of diseases, from cancer to rheumatoid arthritis and from parasites to bacterial infections. Nevertheless, the therapeutic potential of this drug target seems not exhausted and may end up as a possible solution for a larger variety of conditions. Here we present our working model for how ChoKα could play a role in obesity and for how drugs being developed as therapeutics for other diseases using ChoKα as a target, could be repurposed as prophylactic treatments for obesity. We also present preliminary observations in support of our model.</description><subject>adipogenesis</subject><subject>Animals</subject><subject>choline</subject><subject>choline kinase</subject><subject>Choline Kinase - antagonists &amp; inhibitors</subject><subject>Choline Kinase - metabolism</subject><subject>Endocrinology</subject><subject>Humans</subject><subject>obesity</subject><subject>Obesity - drug therapy</subject><subject>thermogenesis</subject><issn>1664-2392</issn><issn>1664-2392</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkU1vEzEQhi0EolXpH-CA9sglYTzjz1OFKj4iVeICZ8v22smWzTrYG6T-e5ImVK0vtsbvPDPSw9h7DksiYz_lNPVliYBiyYVFLekVu-RKiQWSxdfP3hfsurV7OBwB3Frzll2QlcoYhEuGq9bFTRmHKXW_h8m31Plxt_Gd7_q6X3ezr-s0d7nUroTUhvnh5h17k_3Y0vX5vmK_vn75eft9cffj2-r2890ikoR5kaPNkXhQKCVZwymjAatRY6-MjQAaMmGm3mNI3PdKkgq95YgxeJGArtjqxO2Lv3e7Omx9fXDFD-6xUOra-ToPcUwuERcYgKzPIBSFoAkBstReGBGVPrBuTqzdPmxTH9M0Vz--gL78mYaNW5e_jnOpFZfmQPh4JtTyZ5_a7LZDi2kc_ZTKvjnixCVwLY5RPEVjLa3VlJ_mcHBHee5RnjvKc2d5h6YPzzd8avmviv4BaM-UMw</recordid><startdate>20241106</startdate><enddate>20241106</enddate><creator>Lacal, Juan Carlos</creator><creator>Ibrahim, Salam A</creator><creator>Zimmerman, Tahl</creator><general>Frontiers Media S.A</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20241106</creationdate><title>Is choline kinase alpha a drug target for obesity?</title><author>Lacal, Juan Carlos ; Ibrahim, Salam A ; Zimmerman, Tahl</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c350t-fc9fc31b625539813f28097272d689c0070f32f3da2be1ad6536bd9122cba4e03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>adipogenesis</topic><topic>Animals</topic><topic>choline</topic><topic>choline kinase</topic><topic>Choline Kinase - antagonists &amp; inhibitors</topic><topic>Choline Kinase - metabolism</topic><topic>Endocrinology</topic><topic>Humans</topic><topic>obesity</topic><topic>Obesity - drug therapy</topic><topic>thermogenesis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lacal, Juan Carlos</creatorcontrib><creatorcontrib>Ibrahim, Salam A</creatorcontrib><creatorcontrib>Zimmerman, Tahl</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Frontiers in endocrinology (Lausanne)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lacal, Juan Carlos</au><au>Ibrahim, Salam A</au><au>Zimmerman, Tahl</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Is choline kinase alpha a drug target for obesity?</atitle><jtitle>Frontiers in endocrinology (Lausanne)</jtitle><addtitle>Front Endocrinol (Lausanne)</addtitle><date>2024-11-06</date><risdate>2024</risdate><volume>15</volume><spage>1492753</spage><pages>1492753-</pages><issn>1664-2392</issn><eissn>1664-2392</eissn><abstract>Choline kinase alpha (ChoKα) is a therapeutic target being developed for a variety of diseases, from cancer to rheumatoid arthritis and from parasites to bacterial infections. Nevertheless, the therapeutic potential of this drug target seems not exhausted and may end up as a possible solution for a larger variety of conditions. Here we present our working model for how ChoKα could play a role in obesity and for how drugs being developed as therapeutics for other diseases using ChoKα as a target, could be repurposed as prophylactic treatments for obesity. We also present preliminary observations in support of our model.</abstract><cop>Switzerland</cop><pub>Frontiers Media S.A</pub><pmid>39568820</pmid><doi>10.3389/fendo.2024.1492753</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1664-2392
ispartof Frontiers in endocrinology (Lausanne), 2024-11, Vol.15, p.1492753
issn 1664-2392
1664-2392
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_e3142b039af0463bb73200f57a484c67
source PubMed Central Free
subjects adipogenesis
Animals
choline
choline kinase
Choline Kinase - antagonists & inhibitors
Choline Kinase - metabolism
Endocrinology
Humans
obesity
Obesity - drug therapy
thermogenesis
title Is choline kinase alpha a drug target for obesity?
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T01%3A38%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Is%20choline%20kinase%20alpha%20a%20drug%20target%20for%20obesity?&rft.jtitle=Frontiers%20in%20endocrinology%20(Lausanne)&rft.au=Lacal,%20Juan%20Carlos&rft.date=2024-11-06&rft.volume=15&rft.spage=1492753&rft.pages=1492753-&rft.issn=1664-2392&rft.eissn=1664-2392&rft_id=info:doi/10.3389/fendo.2024.1492753&rft_dat=%3Cproquest_doaj_%3E3131501748%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c350t-fc9fc31b625539813f28097272d689c0070f32f3da2be1ad6536bd9122cba4e03%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3131501748&rft_id=info:pmid/39568820&rfr_iscdi=true